A Randomized Phase II Study of Androgen Receptor Directed Therapy on COGnitive Function in Patients Treated with Darolutamide or Enzalutamide

Protocol No
AFT-47-ARACOG
Principal Investigator
Kathryn Bylow
Phase
II
Summary
We are asking you to take part in this research study because you have metastatic or non-metastatic prostate cancer that has worsened on standard hormonal therapy. Your doctor feels that additional therapy is indicated and has recommended that you receive an androgen receptor (AR) directed therapy. In this study, you will be assigned to a study treatment group to evaluate the effects of darolutamide or enzalutamide, both of which are AR directed therapies, on cognitive testing outcomes. In order to measure the differences in cognitive outcomes, participants will be asked to complete several study questionnaires at designated study visits.
Description
Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide (ARACOG)
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL